Microparticles, Vector of Genetic Information During HIV Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the investigators study is to demonstrate in healthy subjects and a cohort of patients infected with HIV, the presence of miRNAs in circulating peripheral blood microparticles (MPs).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.

NCT06694753

HIV Infections

RECRUITING PHASE1

Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients

NCT01899196

Hiv Infection

COMPLETED NA

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults

NCT03844386

HIV-1 Infection

COMPLETED PHASE1

A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

NCT00764946

Human Immunodeficiency Virus

COMPLETED PHASE3

Germinal Transmission After Endogenization of HIV Sequences Without a Competent Virus for Replication and a Potential Protective Role

NCT03640923

Hiv

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV,

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Groupe A

Infected by the HIV Innocents of antiretroviral treatment, with a viral plasmatique load \> 1000 copies / ml

Group Type EXPERIMENTAL

Blood samples

Intervention Type BIOLOGICAL

group B

Infected by the HIV whith antiretroviral treatment for at least 6 months,, with a viral plasmatique load \> 40 copies / ml

Group Type EXPERIMENTAL

Blood samples

Intervention Type BIOLOGICAL

group C

Healthy volunteers

Group Type PLACEBO_COMPARATOR

Blood samples

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood samples

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age of 40 +/-10 years
* Seronegativity for the HIV 2
* Patients of the group A: seropositivity for the HIV 1 confirmed in ELISA and Western Blot for at least 2 years and having never received from antiretroviral treatment, with a viral plasmatique load \> 1000 copies / ml
* Patients of the group B: seropositivity for the HIV 1 confirmed in ELISA and Western Blot for at least 2 years and under stable antiretroviral treatment for at least 6 months, with a viral load undetectable plasmatique (\< 40 copies / ml)
* patients of the group C : Matching on the age (+/-3 years) to a patient
* Be considered healthy by the Investigator after a clinical examination Seronegativity for the HIV 1 confirmed in ELISA the day of the taking

Exclusion Criteria

group A et B

* Age of \< 30 years and \> in 50 years
* Seropositivity for the HIV 2

group C Seropositivity for the HIV 2

\- Be under medicinal treatment

Minimum Eligible Age

30 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes